SALICYLATE TREATMENT IN KAWASAKI-DISEASE - HIGH-DOSE OR LOW-DOSE

被引：17

作者：

AKAGI, T ^{[1
]}

KATO, H ^{[1
]}

INOUE, O ^{[1
]}

SATO, N ^{[1
]}

机构：

[1] KURUME UNIV,SCH MED,DEPT PAEDIAT & CHILD HLTH,67 ASAHI MACHI,KURUME,FUKUOKA 830,JAPAN

来源：

EUROPEAN JOURNAL OF PEDIATRICS | 1991年 / 150卷 / 09期

关键词：

KAWASAKI DISEASE; SALICYLATE; THROMBOXANE B2; PROSTACYCLIN; LIVER FUNCTION;

D O I：

10.1007/BF02072625

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day, n = 30) versus low dose (30 mg/kg per day, n = 30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-keto-prostaglandin F1-alpha (PGF1-alpha) levels were compared before enrollment and on days 4, 7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2 +/- 0.3 versus 5.4 +/- 0.8 days, P < 0.05), however, SGPT levels were significantly elevated (157 +/- 34 versus 48 +/- 11 IU/l, P < 0.05). No differences in the incidence of coronary artery lesions were observed (5/30 versus 7/30). Plasma TxB2 production was completely blocked in both groups, and plasma 6-keto-PGF1-alpha levels in the high dose group on day 14 was lower than that in the low dose group (39 +/- 8 versus 159 +/- 65 pg/ml, P < 0.05). SGPT and plasma 6-keto-PGF1-alpha correlated with serum salicylate concentration. These data suggest that high dose salicylate therapy may be disadvantageous as anti-thrombotic therapy, and supports the notion that low dose therapy is safe in the acute stage of Kawasaki disease.

引用

页码：642 / 646

页数：5